Results 181 to 190 of about 51,902 (295)

Identification of two tyrosine kinase like proteins as important modulators of the STATc-mediated response to hyperosmolarity [PDF]

, 2013
Vu, Linh Hai
core  

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Sometimes Small Is Beautiful: Discovery of the Janus Kinases (JAK) and Signal Transducer and Activator of Transcription (STAT) Pathways and the Initial Development of JAK Inhibitors for IBD Treatment. [PDF]

Dig Dis Sci
Kaunitz JD.
europepmc   +1 more source

Non‐Invasive Scalp Tape‐Strip RNA Sequencing Captures Disease Activity and Treatment‐Response Signatures in Alopecia Areata

Allergy, EarlyView.
Non‐invasive scalp tape‐strip RNA sequencing captures core immune and follicular molecular signatures in alopecia areata. Tape‐strip transcriptomic profiles reflect disease severity and treatment response to baricitinib, with concordance to scalp biopsy‐derived signatures.
Carmen Mochón‐Jiménez, Jesús Gay‐Mimbrera, Viviana Dávila‐Flores, Helen He, Jerry Zhou, Irene Rivera‐Ruiz, Pedro J. Gómez‐Arias, Juan de Luque‐Fernández, Benjamin Ungar, Emma Guttman‐Yassky, Juan Ruano   +10 more
wiley   +1 more source

Early Epidemiologic and Immune Predictors of Atopic Dermatitis: Reduced Cord Blood Regulatory B10 Cells in the Munich Atopy Prediction Study (MAPS)

Allergy, EarlyView.
In this prospective birth cohort from Munich, comprehensive clinical assessments and longitudinal lifestyle questionnaires were combined with cord blood immune profiling. Infants who later developed AD showed altered cord blood immune signatures, including reduced CD4+ T cells, increased B cells and markedly decreased Breg cells. Epidemiologic factors,
S. Preis, S. Kaesler, M. Koeberle, M. Hils, B. Evers, R. L. Silva, Y. Skabytska, L. Schellenberger, H. Hufnagel, M. Schielein, B. Kuschel, Y. Amar, A. Zink, T. Biedermann, Z. Kurgyis   +14 more
wiley   +1 more source

Biological Evaluations and Computer-Aided Approaches of Janus Kinases 2 and 3 Inhibitors for Cancer Treatment: A Review. [PDF]

Pharmaceutics
Vázquez-Jiménez LK, Rivera G, Juárez-Saldivar A, Ortega-Balleza JL, Ortiz-Pérez E, Jaime-Sánchez E, Paz-González A, Lara-Ramírez EE.   +7 more
europepmc   +1 more source

Janus kinases to jakinibs: from basic insights to clinical practice. [PDF]

Rheumatology (Oxford), 2019
Gadina M, Le MT, Schwartz DM, Silvennoinen O, Nakayamada S, Yamaoka K, O'Shea JJ.   +6 more
europepmc   +1 more source

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car, Isabelle Huys, Steven Simoens, Arnold G. Vulto   +3 more
wiley   +1 more source

FDA-approved small-molecule kinase inhibitors [PDF]

, 2015
Clausen, Mads Hartvig, Nielsen, Thomas E., Wu, Peng   +2 more
core   +1 more source

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In a real‐world cohort of patients with highly refractory perianal Crohn's disease, upadacitinib induced clinical remission at 12 months in 26% of patients with fistulizing disease and 25% of those with isolated anal ulcerations. ABSTRACT Introduction Upadacitinib (UPA) is effective for treating luminal Crohn's disease (CD), but data on perianal CD ...
Nicolas Richard, Philippe Seksik, Romain Altwegg, Maria Nachury, David Laharie, Stéphane Nancey, Benoît Coffin, Anne‐Laure Pelletier, Mathieu Uzzan, Aurélien Amiot, Morgane Amil, Lucine Vuitton, Mathurin Fumery, Anne Bozon   +13 more
wiley   +1 more source